Olaptesed Pegol

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameOlaptesed Pegol
Drug Alias NameOlaptesedum pegolum培奥拉特塞培戈-奥拉替塞NOX-A12
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionC-X-C motif chemokine ligand 12 antagonists
TargetsC-X-C motif chemokine ligand 12
Therapy Area/IndicationsPancreatic NeoplasmsColorectal NeoplasmsMultiple Myeloma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumItalyAustria +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNoxxon Pharma
China Registration ClassN/A

Develop Information

Active CompaniesTme Pharma AG
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsGlioblastoma
Inactive IndicationsColorectal NeoplasmsMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A